Physician

Oncology

Dr. Donald A. Richards, MD

Donald A. Richards, MD practices Oncology. He graduated from University of Texas Medical School. Dr. Donald A. Richards is a published doctor. He has 29 papers published. The most current publication "A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody(TM1) in patients with metastatic cancer." Donald A. Richards accepts Medicare.

Publications

An innovative, multi-arm, complete phase 1b study of the novel anti-Cancer agent tasisulam in patients with advanced solid tumors.
A phase I dose-escalation study to a predefined dose of a transforming growth factor-ÃŽÂ²1 monoclonal antibodyÃ‚Â (TÃŽÂ²M1) in patients with metastatic Cancer.
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cel...
PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carbo...
Results of docetaxel plus oxaliplatin (DOCOX) Â± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenoCarcinoma: results of a randomised ...
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal Cancer: A randomized phase 2 study.
Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer.
Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer.
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic Leukemia.
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced Cancers refractory to...
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic Cancer: results of a phase II, randomized, noncomparative study.
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory Cancers.
Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube Cancer.
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research...
Pemetrexed in relapsed small-cell lung Cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.
Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast Cancer: report of a Tamoxifen Exemestan...
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast Cancer.
Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung Cancer: results of a phase II ...
Chemotherapeutic gemcitabine doublets in pancreatic Carcinoma.
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate Cancer in a phase 2 single-agent trial.
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal Cancer: results from the ...
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal Cancer.
Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy.
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal Cancer.
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-Cell lu...
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-Cell lung can...
Systemic therapy for gastric Cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions.

Schools

Univ Of Ky Coll Of Med
Univ Of Tx Med Sch At San Antonio
University Tex Health Science Center

Procedures Preformed

Plasmapheresis
Thoracentesis

Conditions Treated

Acute Leukemia
Adrenal Gland Cancer
Anal and Rectal Cancer
Anemia
View All

Doctors Specialties

Medical Oncology
Oncology

Accepted Insurances

Choice Plus POS II
Blue Card PPO
Blue Choice
Cigna PPO
Great West Healthcare-Cigna PPO
Open Access Plus
First Health (Coventry Health Care) PPO
MultiPlan PPO
PHCS Network PPO
Choice Plus POS
Navigate HMO
Navigate POS
Options PPO

Education

University of Texas Health Science Center
University of Texas Medical School

Drug Facts

NPI NUMBER		1659313559
NPPES Provider LastName		RICHARDS
NPPES Provider FirstName		DONALD
NPPES Provider ZIPCode		757028369
NPPES Provider State		TX
Specialty Description		Medical Oncology
Total Claim Count		1368.0
Distinct Opioid Count		5.0
Opioid Claim Count		179.0
Percent Opioid Claims		13.08

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1659313559
Last Name Of The Provider	RICHARDS
First Name Of The Provider	DONALD
View All

Similar Doctors

	Dr. Frank T. Ward, MD This Doctor is OpenDoctor Recommended.
	Dr. Svetislava J. Vukelja, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Manmeet Mangat, MD This Doctor is OpenDoctor Recommended.
	Dr. Shail Dalal, MD This Doctor is OpenDoctor Recommended.
	Dr. Thomas F. Gregory, MD